% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@INBOOK{Groppa:272870,
author = {Gubinelli, Francesco and Salazar, Jose M. and Kaspar,
Janina and Ortiz, Irene Santisteban and Schafer, Simon T.
and Burbulla, Lena F.},
editor = {Groppa, Sergiu and Schneider, Susanne A.},
title = {{T}ranslational {V}iew on {T}herapeutic {S}trategies and
{U}pcoming {I}ssues: {S}tem {C}ell and {B}rain {O}rganoid
{A}pproaches for {P}arkinson’s {D}isease {T}herapy},
volume = {213},
address = {New York, NY},
publisher = {Springer US},
reportid = {DZNE-2024-01287},
isbn = {978-1-0716-4082-1 (print)},
series = {Neuromethods},
pages = {241 - 275},
year = {2025},
comment = {Translational Methods for Parkinson’s Disease and
Atypical Parkinsonism Research / Groppa, Sergiu (Editor) ;
New York, NY : Springer US, 2025, Chapter 17 ; ISSN:
0893-2336=1940-6045 ; ISBN:
978-1-0716-4082-1=978-1-0716-4083-8 ;
doi:10.1007/978-1-0716-4083-8},
booktitle = {Translational Methods for
Parkinson’s Disease and Atypical
Parkinsonism Research / Groppa, Sergiu
(Editor) ; New York, NY : Springer US,
2025, Chapter 17 ; ISSN:
0893-2336=1940-6045 ; ISBN:
978-1-0716-4082-1=978-1-0716-4083-8 ;
doi:10.1007/978-1-0716-4083-8},
abstract = {There are currently no disease-modifying therapies for
Parkinson’s disease (PD), and the available therapies only
relieve the symptoms and not disease progression. Cell
replacement therapy to restore the degenerating neurons is a
promising approach to treating advanced stages of PD. The
idea behind cell therapy dates back to the 1970s, when the
first transplantation of fetal ventral mesencephalic tissue
was performed on neurotoxic animal models of PD and showed
promising motor recovery and graft survival. Based on this
early proof of concept, several other cell types from
different sources—e.g., embryonic stem cells or induced
pluripotent stem cells—were tested and used in several
preclinical studies, leading to transplantation into a small
number of human subjects. After proving the safety of the
method and the overall positive clinical outcome, several
clinical trials were organized in Europe, in the United
States, and in the rest of the world. In this chapter, we
describe the story of modern stem cell-based clinical trials
for the treatment of PD and highlight the successes and
limitations of these approaches as well as the key
discoveries associated with it. Part of the chapter is also
dedicated to the use of brain organoids as a new promising
interface between in vitro and in vivo models, which could
lead to the development of novel disease-relevant insights
and new promising therapeutic avenues in the near future.},
cin = {AG Burbulla},
ddc = {610},
cid = {I:(DE-2719)5000074},
pnm = {352 - Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-352},
typ = {PUB:(DE-HGF)7},
doi = {10.1007/978-1-0716-4083-8_17},
url = {https://pub.dzne.de/record/272870},
}